Patent intelligence · US
US 10596260
Reoviruses having modified sequences
Reoviruses having modified sequences
Patent details — US 10596260
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 24, 2020
- Expiration
- Mar 19, 2040
- Applicant
- ONCOLYTICS BIOTECH INC.
- Claims
- 19
- CPC classes
- A61K, A61K35/13, A61K35/765, A61K45/06
Quick answer
US 10596260 (Reoviruses having modified sequences) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Mar 24, 2020. Expires Mar 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ONCOLYTICS BIOTECH INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K35/13, A61K35/765, A61K45/06, A61P, A61P35/00
More from ONCOLYTICS BIOTECH INC.
Related pharmaceutical patents in our USPTO index.
-
US 11542526
Oncolytic adenoviral vector and methods of use
granted -
US 11246930
Reoviruses having modified sequences
granted -
US 10167452
Viral purification methods
granted -
US 10039827
Reoviruses having modified sequences
granted -
US 9610352
Lyophilized viral formulations
granted -
US 9610309
Liquid viral formulations
granted -
US 9365823
Virus clearance of neoplastic cells from mixed cellular compositions
granted
Frequently asked questions
What is US patent 10596260?
US 10596260 (Reoviruses having modified sequences) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Mar 24, 2020. Expires Mar 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10596260?
ONCOLYTICS BIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 66 pharmaceutical patents for this assignee.
When does US 10596260 expire?
Our index shows an expiration date of Mar 19, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.